CRS Phenotypes: With and Without Nasal Polyps
Chronic rhinosinusitis is classified by the presence (CRSwNP) or absence (CRSsNP) of nasal polyps based on symptoms persisting ≥12 weeks, and divided into two endotypes: eosinophilic Type 2 inflammation and non-eosinophilic Th1-driven disease.
CRS Phenotypes: With and Without Nasal Polyps is frequently researched by patients in general ENT, yet the search term alone is not enough to settle personal care. Chronic rhinosinusitis is classified by the presence (CRSwNP) or absence (CRSsNP) of nasal polyps based on symptoms persisting ≥12 weeks, and divided into two endotypes: eosinophilic Type 2 inflammation and non-eosinophilic Th1-driven disease. Age, comorbidities, this entry side pattern, duration and previous report language change the clinical reading. the clinical point assessment brings nasal-sinus symptoms, the dictionary entry throat-tonsil context, this topic upper-airway impact and this term sleep links into one ENT frame. This entry uses a function-first way of assessing the finding and points to the questions worth preparing. For this entry, the existing summary aims to connect the reported complaint with examination findings: CRSwNP is characterised by IL-4/IL-5/IL-13-mediated Type 2 inflammation; tissue eosinophilia ≥10 cells per high-power field is diagnostically important. The topic is therefore read with clinical context, not as a one-line definition.
During a the clinical point consultation, the patient's description is compared with the examination finding. The the finding onset date, progression pattern, side difference, quality-of-life effect and prior treatment response are recorded. this entry review may combine ENT examination, the clinical point endoscopic assessment, the dictionary entry oral cavity-oropharynx inspection and this topic audiological testing when useful. this term decisions record fever, the finding pain-bleeding pattern, this entry hearing or nasal blockage, the clinical point sleep impact and the dictionary entry infection recurrence separately. In this entry, the clinical aim is to prove the finding that explains the complaint and separate similar-looking conditions: CT Lund-Mackay score ≥4 indicates significant sinus disease; the Lund-Kennedy endoscopy score evaluates polyp burden and mucosal inflammation. Tests are requested when they help make that distinction. Diagnosis therefore rests on the whole clinical picture rather than one report sentence.
the clinical point care translates diagnosis into a practical pathway. Safety boundaries, functional loss, recovery time, possible complications and review needs are discussed in the same visit. the dictionary entry planning discusses medical treatment, this topic allergy control, this term endoscopic procedures, the finding adenoid-tonsil strategy or this entry airway surgery by indication. Management of the clinical point is individualized according to symptom duration, examination findings, functional impact, patient expectations, prior treatment response and imaging or laboratory results when needed. Balanced planning for this topic reduces avoidable delay and unnecessary intervention.
Review of the dictionary entry compares the baseline finding with the current this topic complaint using the same scale. the clinical point follow-up compares pain, the dictionary entry nasal openness, this topic sleep quality, this term hearing impact and the finding infection recurrence over time. Safe communication about this entry helps patients notice risky symptoms early without increasing anxiety and supports adherence to follow-up advice. If the clinical point develops the dictionary entry context with high fever, breathing difficulty, bleeding or one-sided progression, review is brought forward.
Before the this topic visit, the patient can arrange onset date, side pattern, previous tests and medication history in a short sequence; consultation time can then focus on personal risk and care choices.
Diagnosis
CT Lund-Mackay scoring (range 0–24; ≥4 significant) grades sinus involvement. The Lund-Kennedy endoscopy score evaluates polyp size, oedema and discharge. Serum eosinophilia (>0.3×10⁹/L) and total IgE (>100 IU/mL) assist biologic phenotyping. Tissue biopsy confirming ≥10 eosinophils per HPF establishes eosinophilic CRS; fungal staining is needed in treatment-resistant or atypical cases.
Treatment
CRSsNP management starts with topical corticosteroid plus regular saline irrigation. In CRSwNP systemic steroids (prednisolone 0.5 mg/kg for 2 weeks) reduce polyp burden; FESS is the surgical option for refractory disease. For uncontrolled CRSwNP, biologics such as dupilumab, mepolizumab or omalizumab significantly reduce systemic steroid need and recurrence risk.
Outcomes and Follow-up
Without biologic therapy, CRSwNP recurrence reaches 40–60% at 5 years; eosinophilic CRS carries the worst prognosis. Post-FESS surgical success correlates with biomarkers, and Lund-Mackay score guides surgical planning. In the SINUS-52 trial, dupilumab achieved 50% polyp score reduction and 60% olfactory recovery. Nasal endoscopy every 3–6 months is recommended for surveillance.
When to Seek Care
Bilateral nasal obstruction, anosmia and facial pressure persisting ≥12 weeks despite topical treatment warrants ENT referral. Requiring systemic steroids ≥2 times per year, comorbid asthma, and anosmia significantly impairing quality of life and work are strong indications for biologic therapy evaluation.
Frequently asked questions
What is CRS Phenotypes: With and Without Nasal Polyps?
When is CRS Phenotypes: With and Without Nasal Polyps clinically important?
When is ENT assessment relevant for CRS Phenotypes: With and Without Nasal Polyps?
What information helps assessment of CRS Phenotypes: With and Without Nasal Polyps?
Learn more about this procedure
Detailed guide from Prof. Dr. Özdoğan's clinic
References
This glossary entry is for informational purposes only and does not constitute medical advice. Consult a qualified specialist for diagnosis and treatment.